Feb 13, 2024 8:00am EST Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
Nov 30, 2023 7:00am EST Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy